Drug Database
Back to search

France· FR:62493653

AVONEX 30 microgrammes/0,5 ml, solution injectable

A interferon beta-1a product containing interféron bêta-1a, registered in France by BIOGEN NETHERLANDS (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L03AB07

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedAVONEX 30 microgrammes/0,5 ml, soluti…ATCL03AB07REGISTER NO.FR:62493653PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about interféron bêta-1aAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Interferon beta-1a is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AB07 (interferon beta-1a), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search interferon beta-1a products by name

Interferon beta-1a · ATC L03AB07

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of interferon beta-1a costs, country by country.

Normalised to the WHO defined daily dose (4.3 mcg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Interferon beta-1a · price per daily dose (4.3 mcg)

USD · FX 28 Sept 2026

  • CH Switzerland$13.13
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
INTERFÉRON BÊTA-1A
Manufacturer
BIOGEN NETHERLANDS (PAYS-BAS)
Country
France (FR)
ATC code
L03AB07
ATC class
Interferon beta-1a
Defined daily dose
4.3 mcg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400934323263
    4 seringue(s) préremplie(s) en verre de 0,5 ml avec aiguille(s)
    EUR 475.1

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

347 interactions on record for interferon beta-1a.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check interferon beta-1a against other medicinesHow interaction checks work

Interferon beta-1a · interactions on record

347 records

  • 15 severe
  • 332 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ZidovudineJ05AF01severe
  • ClotrimazoleA01AB18moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Interferon beta-1a in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All interferon beta-1a products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Avonex, Rebif
  • Liechtenstein · Avonex, Rebif
  • Norway · Avonex, Rebif

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6230d0d2-d9a5-4f4f-9e15-e3cd74c990a3
GET /v1/drugs/6230d0d2-d9a5-4f4f-9e15-e3cd74c990a3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "62493653",
  "date_amm": "2003-06-24",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/97/033",
  "substance": "INTERFÉRON BÊTA-1A",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "intramusculaire",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about interferon beta-1a.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console